Media OutReach
Klinik Tuah Welcomes Its 10,000th Knee Pain Patient in Under Five Years
This achievement comes at a time when more Malaysians, particularly older adults are struggling to access early treatment for knee pain. Common barriers include high costs, long waiting times, and concerns about whether the treatment will actually work.
For the clinic’s founder, this milestone carries a meaning far beyond the numbers. It is the fulfilment of a promise.
Dr. Hareez recalled watching a mother live with knee pain for years, as simple daily activities like walking, climbing stairs, and even praying gradually became harder over time. Accompanying a parent to treatment from a young age, only to see the same result each time: a bottle of painkillers and no lasting relief. The pain never went away, regardless of how many bottles were finished. Hearing the cries of pain every night was something that stayed close to heart.
That experience became the foundation of a personal commitment which is to help others going through the same struggle.
That same principle has guided Klinik Tuah since its very first day of operations.
Five Years of Changing How Knee Pain Is Treated
Klinik Tuah started with a single clinic in Cheras in September 2021. Today, Klinik Tuah has grown to six branches across Peninsular Malaysia, with plans to open new branches in Gombak and Penang in the near future.
But according to Dr. Hareez Noorman, one of Klinik Tuah’s co-founders, the growth has always been driven by a bigger vision.
“Whenever knee pain was brought up, the first thing that came to mind for most people was the fear of surgery. But after visiting several countries such as Korea, Japan, Türkiye, and others to study the latest advances in knee treatment, Klinik Tuah was determined to bring these non-surgical technologies back to Malaysia at a price that people could actually afford.”
“Klinik Tuah has invested in the latest medical technology, advanced equipment, and ongoing training for its doctors to make sure that more people can benefit from knee treatment at Klinik Tuah.”
Over five years of operations, Klinik Tuah has seen patients from all walks of life, including senior citizens, working adults, and those who simply want to stay active without being held back by knee pain. The majority of knee pain patients are aged 50 and above, making up around 72% of all cases treated at the clinic.
Growing Awareness of Non-Surgical Treatment
Klinik Tuah has also observed a growing shift in the way Malaysians think about knee treatment. More people are now actively looking for modern, less invasive options that allow them to get back on their feet without relying on long-term painkillers.
This shift is partly driven by better access to health information online, as well as greater exposure to modern knee treatment technologies that are becoming more widely available.
“For a long time, many patients believed that knee pain was just a normal part of getting older. Some lived with it for years, either because they were afraid of surgery, or because they thought they had no other choice besides painkillers or a knee replacement,” said Dr. Hareez Noorman.
Klinik Tuah’s approach focuses on personalised care, supported by the latest diagnostic tools and a range of non-surgical treatment options. These include hyaluronic acid gel injections, Platelet Rich Plasma (PRP) therapy, regenerative cell treatment, Genicular Nerve Block, sclerotherapy, Radio Frequency Ablation (RFA), and other advanced procedures.
Today, Klinik Tuah is recognised as one of Malaysia’s dedicated knee care clinics, known for its patient-centred approach, up-to-date medical technology, and clear communication that helps patients understand their condition and treatment options.
The Journey Continues: 35,000 Patients by 2030
With 10,000 knee pain patients now treated, Klinik Tuah has set its sights on a bigger goal, to help 35,000 patients by the year 2030.
This target is in line with the clinic’s long-term vision of building a future where more Malaysians can move freely, carry out their daily routines comfortably, and live without the burden of chronic knee pain.
To reach this goal, Klinik Tuah plans to expand its network of branches gradually, while continuing to make modern knee treatment more accessible, easier to understand, and tailored to individual needs.
According to the clinic, there are still many Malaysians living with untreated knee pain, whether due to limited access, fear of treatment, or simply not knowing what options are available to them today.
“The goal is clear. Klinik Tuah wants more patients to have the chance to properly understand their condition and to access the right treatment. When pain is managed well, everything else in life gets better,” said Dr. Hareez Noorman.
Dr. Hareez Noorman added that Klinik Tuah’s mission goes beyond treating symptoms — it is about helping patients return to a more active and meaningful life, in line with the clinic’s long-term commitment to reducing the burden of pain in the community.
With advances in modern treatment and increasing public awareness, Klinik Tuah believes the 35,000-patient target by 2030 is a realistic and meaningful step toward a future where effective knee care is within reach for every Malaysian.
Hashtag: #kliniktuah #business #healthcare
https://kliniktuah.com/
https://www.linkedin.com/company/klinik-tuah
https://x.com/kliniktuah
https://www.facebook.com/kliniktuah
https://www.instagram.com/kliniktuah
https://www.youtube.com/@kliniktuah
https://www.tiktok.com/@kliniktuah
The issuer is solely responsible for the content of this announcement.
KLINIK TUAH
Klinik Tuah is a Malaysian medical clinic specialising in knee pain treatment and modern circumcision. Founded in September 2021, the clinic has grown to six branches across Peninsular Malaysia, serving patients from a range of age groups and backgrounds. To date, Klinik Tuah has treated more than 10,000 knee pain patients, with further branch openings planned in the near future.
Through DaaS, enterprise customers can access drone equipment, trained personnel, mission execution, data collection and project deliverables without purchasing and maintaining a complete in-house drone system. The model extends ZenaTech’s business beyond equipment sales and enables the company to generate recurring service revenue from customers’ operational requirements.
ZenaTech reported revenue of CAD 8.4 million for the first quarter of 2026, an increase of 640% from CAD 1.13 million in the same period of 2025. DaaS contributed approximately CAD 7.8 million, accounting for around 93% of quarterly revenue.
In 2025, the company generated annual revenue of CAD 12.9 million, up 558% from approximately CAD 2 million in 2024. DaaS contributed approximately CAD 10.1 million during its first full year of operations, representing around 78% of total annual revenue.
Acquisitions Support Service Network Expansion
ZenaTech has expanded its DaaS operations through a combination of internal technology development and acquisitions. The acquired businesses bring existing customers, professional teams and local operating capabilities, while ZenaTech gradually introduces drones, automated data collection and AI-supported analytics into selected workflows.
In 2025, the company completed 20 acquisitions, including 19 businesses providing engineering data, facility inspection and related professional services, as well as one enterprise software company.
By June 2026, ZenaTech had completed its 24th DaaS-related acquisition and expanded its services into property cleaning, facility inspection and maintenance.
Through its ZenaDrone subsidiary, ZenaTech has also developed drone products for indoor and outdoor operations. The IQ Quad supports site data collection, engineering imagery and 3D modelling, while the IQ Nano uses barcode and RFID scanning to support inventory records, shelf inspections and indoor data collection.
The company’s reported revenue growth, acquisition activity and DaaS contribution provide investors following the AI and drone sectors with measurable indicators of how its technologies are being integrated into commercial operations and converted into service revenue.
Hashtag: #ZenaTech
The issuer is solely responsible for the content of this announcement.
About ZenaTech
ZenaTech (Nasdaq: ZENA) is a technology company specialising in AI-powered drones, Drone-as-a-Service (DaaS), enterprise SaaS solutions and related technologies. Through its ZenaDrone subsidiary, the company develops drone products and software for commercial applications including engineering data collection, agriculture, warehouse management, facility inspection and property maintenance. ZenaTech combines its technology capabilities with a growing professional service network to support the adoption of drone-based solutions across a range of operational environments.
Media OutReach
A Defining Milestone for Gene Solutions: SPOT-MAS Multi-Cancer Screening Test Receives U.S. FDA Breakthrough Device Designation
The proposed indications for use describe SPOT-MAS 10 as a qualitative in vitro diagnostic test performed on plasma derived from a single direct-draw venous whole blood specimen. The test analyzes circulating cell-free DNA methylation and fragmentomic signatures using a machine-learning-based algorithm to detect a cancer-associated signal. It is intended for use as an adjunctive screening test in asymptomatic adults aged 40 years and older to assist in detecting cancers within the scope of the assay. These include five common cancers — breast, lung, liver, colorectal and gastric cancers — and five aggressive, less common cancers that currently lack standard screening methods — ovarian, pancreatic, esophageal, endometrial and head & neck cancers.
SPOT-MAS has been developed through years of rigorous scientific research and clinical development. In March 2025, SPOT-MAS became the first multi-cancer screening blood test in Asia to complete a large prospective cohort validation, with the K-DETEK study evaluating more than 9,000 asymptomatic participants and demonstrating strong performance, including high specificity and the ability to identify cancer-associated signals across multiple cancer types.
Since then, SPOT-MAS has been used in more than 100,000 individuals in real-world practice, with consistent performance observed beyond controlled study settings. Real-world data were presented at ESMO Asia 2025 and were featured at ASCO Breakthrough 2026 in Singapore.
The platform is built on a multi-omic approach— integrating genetics, epigenetics, and fragmentomics — together with AI-driven analysis, large-scale prospective validation, growing real-world evidence and focus on cancer types with high clinical relevance in the regions where the test is deployed.
For the United States, Breakthrough Device Designation provides Gene Solutions with a prioritized channel of engagement with the FDA as the company advances its U.S. development and validation plans.
Looking ahead, Gene Solutions will continue to collaborate with academic, clinical, laboratory, commercial and strategic partners to support responsible adoption of SPOT-MAS in accordance with local regulations, clinical guidelines and best practices.
Important Regulatory Notice: SPOT-MAS 10 has received U.S. FDA Breakthrough Device Designation. Breakthrough Device Designation is not FDA approval, clearance or marketing authorization. The device remains subject to applicable FDA regulatory review requirements, and the designation does not guarantee future FDA approval, clearance or authorization.
For more information, visit https://spotmas.com.hk
Contact:
hk***@***********ns.com
Source: Gene Solutions Hong Kong Limited.
SPOTMAS_062026_04
Hashtag: #SPOTMAS
https://spotmas.com.hk/The issuer is solely responsible for the content of this announcement.
Media OutReach
St Francis Methodist School International Shares 2023–2024 WACE Outcomes and Student Journeys
Overview of the WACE Curriculum at SFMS
SFMS International is among a small number of institutions in Singapore offering the WACE curriculum and has delivered this programme for over 23 years. The WACE is a recognised senior secondary qualification awarded by the School Curriculum and Standards Authority (SCSA) on behalf of the Ministry of Education, Western Australia. It prepares students for university admission both locally and internationally.
SFMS is also currently the only school in Singapore offering a Senior High Preparatory Pathway (WACE) for students in Years 9–10. This introduces students to the structure and expectations of the curriculum earlier, building familiarity with subject content and assessment formats before progressing to the senior years. Additionally, subject selection in Years 11A and 12A is structured to meet university entry requirements and reflect students’ academic interests.
Academic Outcomes and University Placements
In 2023, 8 out of 12 WACE graduates from SFMS International achieved ATAR scores above 90, meeting the eligibility criteria for universities such as the National University of Singapore (NUS) and Nanyang Technological University (NTU). The cohort’s top scorer, Wang Dawei, recorded an ATAR of 96.15 and enrolled at NTU to study Business and International Trading. In addition to local placements, graduates were admitted to international universities such as the University of Melbourne and Fudan University in China.
In 2024, 2 out of 8 graduates also attained ATAR scores above 90. The highest scorer, Youn Chae-Won, achieved an ATAR of 95.3. Her university placement is currently pending.
Student Journeys and Holistic Development
Students in the WACE programme at SFMS International engage in both academic and co-curricular activities as part of their overall learning experience. Recent graduates have taken part in service learning, subject specialisation, and personal reflection throughout their time in the pre-university programme.
Youn Chae-Won, the 2024 valedictorian, joined SFMS International from Korea in 2021. Over time, she adjusted to a new academic environment and explored subjects such as accounting, which influenced her interest in finance-related pathways. She also took part in various aspects of school life, including a service learning trip to Bintan in 2023, where students supported local sanitation efforts. Her involvement in both academic and co-curricular settings marked a broad engagement with school life during her time at SFMS.
Andrew Zhuang, who enrolled in SFMS International in 2019, pursued subjects such as Business Management, Accounting, and English as an Additional Language (EALD). Beyond academics, he was involved in community fundraising and joined the same Bintan service trip. He also attended weekly chapel sessions and received support from peers and teachers during a period of health-related absence.
These outcomes reflect the ongoing role of the WACE programme at SFMS International in supporting students through both academic pathways and broader educational experiences. Under the leadership of Principal Mr Lee Hak Boon, the school continues to emphasise academic planning, subject selection, and student wellbeing as part of its overall approach to pre-university education.
Hashtag: #StFrancisMethodistSchoolInternational
https://www.sfms.edu.sg/
https://www.facebook.com/sfms.singapore
https://www.instagram.com/sfms_sg/
https://www.youtube.com/channel/UC_bb9hcNhAk7WgYBE_FI61A/featured
The issuer is solely responsible for the content of this announcement.
About St Francis Methodist School International
Established in 1960, St Francis Methodist School International (SFMS) is an educational institution in Singapore that offers primary, secondary, and pre-university programmes. The school provides several academic pathways, including the International Baccalaureate (IB), Cambridge IGCSE, and the Western Australian Certificate of Education (WACE), preparing students for further studies in local and overseas institutions.
